Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6N7C

Structure of the human JAK1 kinase domain with compound 56

6N7C の概要
エントリーDOI10.2210/pdb6n7c/pdb
分子名称Tyrosine-protein kinase JAK1, N-[5-(3-methoxynaphthalen-2-yl)-1H-pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide, GLYCEROL, ... (4 entities in total)
機能のキーワードjak1, il13, il-13, jak2, jak3, tyk2, immune system
由来する生物種Homo sapiens (Human)
タンパク質・核酸の鎖数2
化学式量合計70354.06
構造登録者
Lupardus, P.J.,Brown, D. (登録日: 2018-11-27, 公開日: 2019-04-24, 最終更新日: 2024-11-06)
主引用文献Zak, M.,Hanan, E.J.,Lupardus, P.,Brown, D.G.,Robinson, C.,Siu, M.,Lyssikatos, J.P.,Romero, F.A.,Zhao, G.,Kellar, T.,Mendonca, R.,Ray, N.C.,Goodacre, S.C.,Crackett, P.H.,McLean, N.,Hurley, C.A.,Yuen, P.W.,Cheng, Y.X.,Liu, X.,Liimatta, M.,Kohli, P.B.,Nonomiya, J.,Salmon, G.,Buckley, G.,Lloyd, J.,Gibbons, P.,Ghilardi, N.,Kenny, J.R.,Johnson, A.
Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling.
Bioorg.Med.Chem.Lett., 29:1522-1531, 2019
Cited by
PubMed Abstract: Disruption of interleukin-13 (IL-13) signaling with large molecule antibody therapies has shown promise in diseases of allergic inflammation. Given that IL-13 recruits several members of the Janus Kinase family (JAK1, JAK2, and TYK2) to its receptor complex, JAK inhibition may offer an alternate small molecule approach to disrupting IL-13 signaling. Herein we demonstrate that JAK1 is likely the isoform most important to IL-13 signaling. Structure-based design was then used to improve the JAK1 potency of a series of previously reported JAK2 inhibitors. The ability to impede IL-13 signaling was thereby significantly improved, with the best compounds exhibiting single digit nM IC's in cell-based assays dependent upon IL-13 signaling. Appropriate substitution was further found to influence inhibition of a key off-target, LRRK2. Finally, the most potent compounds were found to be metabolically labile, which makes them ideal scaffolds for further development as topical agents for IL-13 mediated diseases of the lungs and skin (for example asthma and atopic dermatitis, respectively).
PubMed: 30981576
DOI: 10.1016/j.bmcl.2019.04.008
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.69 Å)
構造検証レポート
Validation report summary of 6n7c
検証レポート(詳細版)ダウンロードをダウンロード

237423

件を2025-06-11に公開中

PDB statisticsPDBj update infoContact PDBjnumon